PUTTINI MIRIAM

GAMBACORTI PASSERINI, C., Antolini, L., Mahon, F., Guilhot, F., Deininger, M., Fava, C., et al. (2011). Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 103(7), 553-561 [10.1093/jnci/djr060]. Detail

GAMBACORTI PASSERINI, C., Antolini, L., Piazza, R., Guilhot, F., Deininger, M., Fava, C., et al. (2011). Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years. In ASH 2011; 53rd Congress of the American Society of Hematology (pp.1608-1608). AMER SOC HEMATOLOGY. Detail

Tornaghi, L., Meneghetti, I., Dilda, I., Puttini, M., Piazza, R., Antolini, L., et al. (2009). Imatinib long term effects study: three years of follow-up and assessment. In SIE 2009; 42nd Congress of the Italian Society of Hematology. Il Pensiero Scientifico. Detail

Puttini, M., Redaelli, S., Moretti, L., Brussolo, S., Gunby, R., Mologni, L., et al. (2008). Characterization of compound 584, an Abl kinase inhibitor with lasting effects. HAEMATOLOGICA, 93(5), 653-661 [10.3324/haematol.12212]. Detail

Gunby, R., Sala, E., Tartari, C., Puttini, M., GAMBACORTI PASSERINI, C., Mologni, L. (2007). Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 7(6), 594-611 [10.2174/187152007784111340]. Detail